Pfizer is to acquire commercial-stage biopharmaceutical company Biohaven in a deal worth $11.6 billion. Biohaven is developing therapies for the treatment of migraine. The company’s lead product NURTEC ODT is a dual-acting migraine therapy which has been approved in the US for adult patients. The therapy has also been approved in the EU for both […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!